UNSPSC 51334102: Perospirone

This classification denotes an anxiolytic with the molecular formula C23H30N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N303OK87DT, chemically known as 1h-isoindole-1,3(2h)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, cis- but generally known as perospirone, which bears US NIH Compound Identifier 115368. European Medicines Agency schedules Perospirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09735MIG.

UNSPSC 51334102 Perospirone is a Commodity code that in practice captures state and local procurement of pharmaceutical products and drug-management systems rather than perospirone specifically. Recent solicitations show state and local governments buying naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models to manage pharmacy benefit costs. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The scope spans manufacturer relationships, wholesaler-mediated distribution, compliance with Good Manufacturing Practices and Drug Supply Chain Security Act standards, and integration with existing pharmacy benefit manager and group purchasing organization channels.

Recent activity concentrates in Florida and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to a county health facility, response deadline July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs for self-insured employee and state agency plans. Vendors bidding under this code must hold current cGMP and DSCSA certifications, maintain relationships with authorized wholesalers, and meet insurance requirements including commercial general liability and professional liability coverage.